Skip to main content

A Brief Report on Proposed Areas of International Harmonization of Real-World Evidence Relevance, Reliability and Quality Standards Among Medical Product Regulators.

Publication ,  Journal Article
Nafie, M; Parker, VJ; McClellan, M; Hendricks-Sturrup, RM
Published in: Pharmacoepidemiology and drug safety
March 2025

International harmonization of real-world data and evidence (RWD/E) standards is a goal among real-world data/real-world evidence (RWD/E) policy stakeholders. The Duke-Robert J. Margolis Institute for Health Policy developed an online 'International Harmonization of RWE Standards Dashboard' to provide timely updates around these goals.Guidance for industry (draft and final) and related literature available online by medical product regulators globally was sought and, where needed, translated into English language using a certified translator. Consultations were then held with practicing experts to identify, collate, and interpret documents. An online Tableau tool was assembled to collate guidance documents and regulatory definitions of the following key terms used among the community to describe fit-for-use RWE in regulatory submissions: relevance, reliability, and quality.As of February 2025, the United States Food and Drug Administration (FDA) has released the most RWE guidance documents to date (n = 13; 4 draft, 9 final). Four (4) regulators globally (US FDA, EMA, Taiwan FDA, Brazil ANVISA) have directly defined at least two (2) out of the three key terms (reliability, relevance, quality), indicating alignment around the importance of these terms used in the context of RWD/E. Across these terms, we propose areas of definitional alignment: data representativeness and research and regulatory concern (relevance), accuracy in data interpretation and quality and integrity during data accrual (reliability), and data quality assurance across sites and time (quality). We propose areas of definitional misalignment regarding clinical context, data availability and representativeness, and ensuring study sample sizes and/or datasets are adequate to address a given study question.Our assessment of definitions provided among these four regulators lends us to propose distinct areas for harmonization based on our assessment of where regulators appear to align and highlight opportunities to address misalignment.

Duke Scholars

Published In

Pharmacoepidemiology and drug safety

DOI

EISSN

1099-1557

ISSN

1053-8569

Publication Date

March 2025

Volume

34

Issue

3

Start / End Page

e70127

Related Subject Headings

  • United States Food and Drug Administration
  • United States
  • Reproducibility of Results
  • Pharmacology & Pharmacy
  • Pharmacoepidemiology
  • International Cooperation
  • Humans
  • 4202 Epidemiology
  • 3214 Pharmacology and pharmaceutical sciences
  • 1117 Public Health and Health Services
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Nafie, M., Parker, V. J., McClellan, M., & Hendricks-Sturrup, R. M. (2025). A Brief Report on Proposed Areas of International Harmonization of Real-World Evidence Relevance, Reliability and Quality Standards Among Medical Product Regulators. Pharmacoepidemiology and Drug Safety, 34(3), e70127. https://doi.org/10.1002/pds.70127
Nafie, Maryam, Valerie J. Parker, Mark McClellan, and Rachele M. Hendricks-Sturrup. “A Brief Report on Proposed Areas of International Harmonization of Real-World Evidence Relevance, Reliability and Quality Standards Among Medical Product Regulators.Pharmacoepidemiology and Drug Safety 34, no. 3 (March 2025): e70127. https://doi.org/10.1002/pds.70127.
Nafie M, Parker VJ, McClellan M, Hendricks-Sturrup RM. A Brief Report on Proposed Areas of International Harmonization of Real-World Evidence Relevance, Reliability and Quality Standards Among Medical Product Regulators. Pharmacoepidemiology and drug safety. 2025 Mar;34(3):e70127.
Nafie, Maryam, et al. “A Brief Report on Proposed Areas of International Harmonization of Real-World Evidence Relevance, Reliability and Quality Standards Among Medical Product Regulators.Pharmacoepidemiology and Drug Safety, vol. 34, no. 3, Mar. 2025, p. e70127. Epmc, doi:10.1002/pds.70127.
Nafie M, Parker VJ, McClellan M, Hendricks-Sturrup RM. A Brief Report on Proposed Areas of International Harmonization of Real-World Evidence Relevance, Reliability and Quality Standards Among Medical Product Regulators. Pharmacoepidemiology and drug safety. 2025 Mar;34(3):e70127.

Published In

Pharmacoepidemiology and drug safety

DOI

EISSN

1099-1557

ISSN

1053-8569

Publication Date

March 2025

Volume

34

Issue

3

Start / End Page

e70127

Related Subject Headings

  • United States Food and Drug Administration
  • United States
  • Reproducibility of Results
  • Pharmacology & Pharmacy
  • Pharmacoepidemiology
  • International Cooperation
  • Humans
  • 4202 Epidemiology
  • 3214 Pharmacology and pharmaceutical sciences
  • 1117 Public Health and Health Services